Apellis Pharmaceuticals (FRA:1JK) Total Liabilities : €520.0 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Apellis Pharmaceuticals Total Liabilities?

Apellis Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was €520.0 Mil.

Apellis Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2023 (€549.03 Mil) to Dec. 2023 (€544.89 Mil) and declined from Dec. 2023 (€544.89 Mil) to Mar. 2024 (€520.03 Mil).

Apellis Pharmaceuticals's annual Total Liabilities declined from Dec. 2021 (€604.55 Mil) to Dec. 2022 (€557.29 Mil) and declined from Dec. 2022 (€557.29 Mil) to Dec. 2023 (€544.89 Mil).

Apellis Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Apellis Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Total Liabilities Chart

Apellis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

319.51

621.44

604.55

557.29

544.89

Apellis Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															529.34	526.27	549.03	544.89	520.03

Apellis Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Apellis Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	227.043	+	(95.815	+	222.032
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	544.9

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	723.265	-	178.376
	=	544.9

Apellis Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	198.068	+	(94.649	+	227.317
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	520.0

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	765.376	-	245.342
	=	520.0

Apellis Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Apellis Pharmaceuticals (FRA:1JK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (FRA:1JK) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

APLS:USA

Address

100 Fifth Avenue, Waltham, MA, USA, 02451

Website

https://www.apellis.com

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

Apellis Pharmaceuticals (FRA:1JK) Headlines

No Headlines